The mechanisms of action of
intoplicine (RP-60475), a 7H-benzo[e]pyrido[4,3-b]
indole derivative that is presently in early clinical trials, have been investigated.
Intoplicine induced both
topoisomerase I- and II-mediated
DNA strand breaks, using purified topoisomerases. The topoisomerase cleavage site patterns induced by
intoplicine were unique, relative to those of
camptothecin, 4'-(9-acridinylamino)methanesulfon-m-anisidide (
m-AMSA), and other known
topoisomerase inhibitors. Both
topoisomerase I- and II-induced DNA breaks decreased at
drug concentrations higher than 1 microM, which is consistent with the
DNA-intercalating activity of
intoplicine. DNA damage was investigated in KB cells in culture by using alkaline elution.
Intoplicine induced single-strand breaks (SSB) in a bell-shaped manner with respect to
drug concentration (maximum frequency at 1 microM approximately 220 rad-equivalents). SSB formation was fast, whereas reversal after
drug removal was slow. Similar bell-shaped curves were obtained for
DNA double-strand breaks (
DSB) and
DNA-
protein cross-links. SSB and
DNA-
protein cross-link frequencies were approximately equal, and no
protein-free breaks were detectable, indicating the
protein concealment of the breaks, as expected for topoisomerase inhibition. Comparison of SSB and
DSB frequencies indicated that
intoplicine produced a significant amount of SSB not related to
DSB, which is consistent with concomitant inhibition of both
DNA topoisomerases I and II in cells. Data derived from resistant cell lines indicated that multidrug-resistant cells were cross-resistant to
intoplicine but that
m-AMSA- and
camptothecin-resistant cells were sensitive to
intoplicine. Hence,
intoplicine might circumvent
topoisomerase I-mediated and
topoisomerase II-mediated resistance by
poisoning both
enzymes simultaneously.